Navigating clinical pipeline decisions means balancing science, business, and risk. Leaders from biotech and pharma share how robust analysis, adaptability, and cross-functional teamwork drive portfolio success. Aligning scientific rigor with commercial reality is key to advancing programs and achieving better patient outcomes.